{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:15:31Z","timestamp":1785338131481,"version":"3.55.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>A fraction of lung adenocarcinoma patients with gene mutations who receive targeted therapy would experience acquired resistance and undergo small cell lung cancer (SCLC) transformation. The mechanisms behind the transformation of tumor pathological types and the treatment strategies are not fully clear. There have been case reports of the transformation from adenocarcinoma to SCLC, but the partial transformation from adenocarcinoma to SCLC has not been reported. We reported a case of a patient with partial transformation from lung adenocarcinoma to SCLC for the first time. The patient was diagnosed as lung adenocarcinoma with epidermal growth factor receptor (EGFR) 19 exon mutation and Tumor protein p53 (TP53) mutation. She received Epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, the tumor progression occurred and the lung aspiration pathology revealed a transformation from non-small cell lung cancer (NSCLC) to SCLC. The treatment regimen was changed to cisplatin and etoposide (EP) chemotherapy, resulting in a 2-month PFS. It was worth mentioning that adenocarcinoma cells were found in the patient\u2019s emerging pericardial effusion, suggesting the co-existence of both adenocarcinoma and SCLC components. This is the first report of partial transformation from NSCLC to SCLC in the context of definitive pathology. It highlights that when no more pathological biopsy is feasible, we should be alert to the partial transformation and adopt the appropriate treatment.<\/jats:p>","DOI":"10.3389\/fonc.2025.1441182","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T08:07:21Z","timestamp":1741680441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Partial transformation from non-small cell lung cancer to small cell lung cancer: a case report and literatures review"],"prefix":"10.3389","volume":"15","author":[{"given":"Yicong","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danruo","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqiong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1158\/2159-8290.Cd-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discovery"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2028","article-title":"A brief report of transformation from NSCLC to SCLC: molecular and therapeutic characteristics","volume":"14","author":"Ferrer","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)71180-5","article-title":"Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin","volume":"16","author":"Oser","year":"2015","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9083","article-title":"Genetic alterations and protein expression in combined small cell lung cancers and small cell lung cancers arising from lung adenocarcinomas after therapy with tyrosine kinase inhibitors","volume":"7","author":"Shi","year":"2016","journal-title":"Oncotarget"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2022.102.41","article-title":"Two cases of TKI-resistant small cell lung cancer transformation in advanced adenocarcinoma and literature review","volume":"25","author":"Wu","year":"2022","journal-title":"Chin J Lung Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.11877\/j.issn.1672-1535.2021.19.07.10","article-title":"Analysis of clinical features of lung adenocarcinoma transforming into small cell lung cancer","volume":"19","author":"Zhao","year":"2021","journal-title":"Oncol Prog"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.06.003","article-title":"Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma","volume":"82","author":"Watanabe","year":"2013","journal-title":"Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.71.9096","article-title":"Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.07.007","article-title":"Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment: A systematic review and pooled analysis","volume":"59","author":"Roca","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2023.05.006","article-title":"Current knowledge of small cell lung cancer transformation from non-small cell lung cancer","volume":"94","author":"Giaccone","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-07-2248","article-title":"Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non\u2013small cell lung cancer","volume":"14","author":"Engelman","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.12.005","article-title":"MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition","volume":"31","author":"Mollaoglu","year":"2017","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7377","article-title":"RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer","volume":"6","author":"Niederst","year":"2015","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153737","article-title":"Targeting RB1 loss in cancers","volume":"13","author":"Linn","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: direct and indirect strategies","volume":"14","author":"Hu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-020-0127-9","article-title":"Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition","volume":"4","author":"Lin","year":"2020","journal-title":"NPJ Precis Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2217\/pme-2017-0069","article-title":"ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment","volume":"15","author":"Hobeika","year":"2018","journal-title":"Per Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.04.005","article-title":"Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma","volume":"81","author":"Zhang","year":"2013","journal-title":"Lung Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182a407fa","article-title":"Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology","volume":"8","author":"Norkowski","year":"2013","journal-title":"J Thorac Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000002752","article-title":"Small-cell lung cancer transformation in patients with pulmonary adenocarcinoma","volume":"95","author":"Jiang","year":"2016","journal-title":"Medicine"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1435222","article-title":"Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review","volume":"19","author":"Liu","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31816de2b8","article-title":"The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition","volume":"3","author":"Sculier","year":"2008","journal-title":"J Thorac Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-023-02799-5","article-title":"Whole-exome sequencing explored mechanism of selpercatinib resistance in RET-rearranged lung adenocarcinoma transformation into small-cell lung cancer: a case report","volume":"23","author":"Peng","year":"2023","journal-title":"BMC Pulmonary Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00478","article-title":"Small cell transformation in a patient with RET fusion\u2013positive lung adenocarcinoma on pralsetinib","volume":"6","author":"Dimou","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0000000000001403","article-title":"Reuse of osimertinib after small cell lung cancer transformation in lung adenocarcinoma with de-novo epidermal growth factor receptor T790M mutation: case report","volume":"34","author":"Wang","year":"2022","journal-title":"Anti-Cancer Drugs"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14563","article-title":"Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report","volume":"13","author":"Ninomaru","year":"2022","journal-title":"Thorac Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14144","article-title":"Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma","volume":"12","author":"Wang","year":"2021","journal-title":"Thorac Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14832","article-title":"Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer","volume":"14","author":"Hao","year":"2023","journal-title":"Thorac Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1441182\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T08:07:25Z","timestamp":1741680445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1441182\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":32,"alternative-id":["10.3389\/fonc.2025.1441182"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1441182","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"article-number":"1441182"}}